Targeted therapy for advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer

This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To evaluate the safety and efficacy of anaplastic lymphoma kinase (ALK) inhibitors given as monotherapy to treat advanced ALK ‐ rearranged non‐small cell lung cancer (NSCLC).

Saved in:
Bibliographic Details
Published in:Cochrane database of systematic reviews 2019-10, Vol.2019 (10)
Main Authors: Cameron, Laird B, Hitchen, Nadia, Jordan, Vanessa, Manser, Renée, Solomon, Benjamin J
Format: Article
Language:English
Subjects:
Medicine General & Introductory Medical Sciences
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To evaluate the safety and efficacy of anaplastic lymphoma kinase (ALK) inhibitors given as monotherapy to treat advanced ALK ‐ rearranged non‐small cell lung cancer (NSCLC).
ISSN:1469-493X
DOI:10.1002/14651858.CD013453